TELIX Pharmaceuticals Ltd (AU:TLX) — Market Cap & Net Worth
Market Cap & Net Worth: TELIX Pharmaceuticals Ltd (TLX)
TELIX Pharmaceuticals Ltd (AU:TLX) has a market capitalization of $3.27 Billion (AU$4.62 Billion) as of August 1, 2026. Listed on the AU stock exchange, this Australia-based company holds position #4602 globally and #112 in its home market, demonstrating a -6.33% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying TELIX Pharmaceuticals Ltd's stock price AU$14.21 by its total outstanding shares 334724485 (334.72 Million). See TLX capex to operating cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
TELIX Pharmaceuticals Ltd Market Cap History: 2017 to 2026
TELIX Pharmaceuticals Ltd's market capitalization history from 2017 to 2026. Data shows growth from $146.84 Million to $3.37 Billion (39.74% CAGR).
Index Memberships
TELIX Pharmaceuticals Ltd is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Australia All Ordinaries
AORD
|
$2.03 Trillion | 0.16% | #98 of 495 |
|
S&P/ASX All Australian 200
AXAT
|
$1.94 Trillion | 0.17% | #96 of 200 |
|
S&P/ASX 200
AXJO
|
$1.91 Trillion | 0.17% | #92 of 200 |
|
S&P/ASX 200 Accumulated
AXJOA
|
$1.91 Trillion | 0.17% | #92 of 200 |
|
S&P/ASX 300
AXKO
|
$2.17 Trillion | 0.15% | #102 of 300 |
|
ASX Small Ordinaries
AXSO
|
$290.35 Billion | 1.13% | #22 of 200 |
Weight: TELIX Pharmaceuticals Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
TELIX Pharmaceuticals Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how TELIX Pharmaceuticals Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
7.44x
TELIX Pharmaceuticals Ltd's market cap is 7.44 times its annual revenue
Latest Price to Earnings (P/E) Ratio
116.76x
TELIX Pharmaceuticals Ltd's market cap is 116.76 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $146.84 Million | $403.47K | -$6.38 Million | 363.95x | N/A |
| 2018 | $153.95 Million | $195.14K | -$13.83 Million | 788.89x | N/A |
| 2019 | $367.10 Million | $3.48 Million | -$27.87 Million | 105.34x | N/A |
| 2020 | $895.25 Million | $5.21 Million | -$44.89 Million | 171.73x | N/A |
| 2021 | $1.84 Billion | $7.60 Million | -$80.51 Million | 241.64x | N/A |
| 2022 | $1.72 Billion | $160.10 Million | -$104.08 Million | 10.75x | N/A |
| 2023 | $2.39 Billion | $502.55 Million | $5.21 Million | 4.75x | 458.13x |
| 2024 | $5.83 Billion | $783.21 Million | $49.92 Million | 7.44x | 116.76x |
Competitor Companies of TLX by Market Capitalization
Companies near TELIX Pharmaceuticals Ltd in the global market cap rankings as of August 1, 2026.
Key companies related to TELIX Pharmaceuticals Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
TELIX Pharmaceuticals Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, TELIX Pharmaceuticals Ltd's market cap moved from $146.84 Million to $ 3.37 Billion, with a yearly change of 39.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$3.37 Billion | +26.88% |
| 2025 | AU$2.65 Billion | -54.49% |
| 2024 | AU$5.83 Billion | +144.15% |
| 2023 | AU$2.39 Billion | +38.65% |
| 2022 | AU$1.72 Billion | -6.19% |
| 2021 | AU$1.84 Billion | +105.03% |
| 2020 | AU$895.25 Million | +143.87% |
| 2019 | AU$367.10 Million | +138.46% |
| 2018 | AU$153.95 Million | +4.84% |
| 2017 | AU$146.84 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of TELIX Pharmaceuticals Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.27 Billion USD |
| MoneyControl | $3.27 Billion USD |
| MarketWatch | $3.27 Billion USD |
| marketcap.company | $3.27 Billion USD |
| Reuters | $3.27 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About TELIX Pharmaceuticals Ltd
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which … Read more